Revised policy for therapies for COVID-19

Having trouble viewing this email? View it as a Web page.

Health Care Authority (HCA) logo

Apple Health (Medicaid) Provider Alert

Attention providers

What changed? 
The Health Care Authority (HCA) has updated its COVID-19 therapies policy with information regarding a new COVID-19 monoclonal antibody.

New COVID-19 monoclonal antibodies
Retroactive for dates of service on and after February 24, 2022, providers may bill HCA for the following monoclonal antibody treatment:

     HCPCS code                             Short description
     Q0221                                      Tixagev and cilgay, 600mg

See Therapies for COVID-19, under COVID-19 resourcesTesting and Treatment for more information regarding the policy and procedure codes involved.

COVID-19 Fee Schedule
HCA revised the COVID-19 Fee Schedule. See HCA’s Provider billing guides and fee schedules, under COVID-19.